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broken wheat kernels. The structure of the breads was 
characterized extensively. The use of stable isotopes ena-
bled calculation of glucose kinetics: rate of appearance of 
exogenous glucose, endogenous glucose production, and 
glucose clearance rate. Additionally, postprandial plasma 
concentrations of glucose, insulin, glucagon, incretins, 
cholecystokinin, and bile acids were analyzed.
Results Despite the attempt to obtain a bread with a low 
glycemic response by replacing flour by broken kernels, the 
glycemic response and glucose kinetics were quite similar 
after consumption of CB and KB. Interestingly, the gluca-
gon-like peptide-1 (GLP-1) response was much lower after 
KB compared to CB (iAUC, P < 0.005). A clear postpran-
dial increase in plasma conjugated bile acids was observed 
after both meals.
Conclusions Substitution of 85 % wheat flour by bro-
ken kernels in bread did not result in a difference in glu-
cose response and kinetics, but in a pronounced difference 
in GLP-1 response. Thus, changing the processing condi-
tions of wheat for baking bread can influence the metabolic 
response beyond glycemia and may therefore influence 
health.
Keywords Glucagon-like peptide-1 · Glycemic index · 
Glucose kinetics · Bile acids · Wheat kernels · Bread 
processing
Introduction
Consumption of foods with a low glycemic index (GI) 
instead of those with a high GI is considered beneficial for 
health, being associated with a decreased risk for the devel-
opment of obesity, insulin resistance, and type 2 diabetes 
(T2DM) [1–5], although this association is not always 
Abstract 
Purpose Underlying mechanisms of the beneficial health 
effects of low glycemic index starchy foods are not fully 
elucidated yet. We varied the wheat particle size to obtain 
fiber-rich breads with a high and low glycemic response 
and investigated the differences in postprandial glucose 
kinetics and metabolic response after their consumption.
Methods Ten healthy male volunteers participated in 
a randomized, crossover study, consuming 13C-enriched 
breads with different structures; a control bread (CB) made 
from wheat flour combined with wheat bran, and a ker-
nel bread (KB) where 85 % of flour was substituted with 
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found [6]. Based on results from a prospective cohort 
study, it was suggested that replacement of high GI bread 
by low GI bread in the diet may reduce the risk of devel-
oping T2DM [7]. Possible explanations were, for instance, 
that consumption of a low GI diet might be associated with 
less weight gain [4] or decreased development of β-cell 
failure and insulin resistance [1, 3]. However, the underly-
ing mechanisms responsible for the beneficial effects need 
further study.
The postprandial glycemic response obviously depends 
on intestinal glucose influx, but is also influenced by sup-
pression of endogenous glucose production (EGP) and 
increased glucose uptake in tissues, processes that are 
mainly regulated by the pancreatic hormones insulin and 
glucagon. The incretin hormones glucose-dependent insu-
linotropic polypeptide (GIP) and glucagon-like peptide-1 
(GLP-1), released postprandial from intestinal K and L 
cells, respectively, are known to potentiate the insulin 
response to a carbohydrate-rich meal and are therefore 
important factors in glucose metabolism. Besides their role 
as incretin hormones, GIP is involved in fat metabolism 
[8], and GLP-1 is involved in decreasing gastric emptying 
rate [9], suppression of glucagon [10], as well as increas-
ing satiety [11], and, in rodents, preserving β-cell function 
[12]. Nowadays, bile acids (BAs) are also being recog-
nized as signaling molecules in glucose metabolism. For 
instance, overexpression of the BA receptor TGR5 [13] and 
administration of taurocholic acid (TCA) [14] in mice was 
associated with elevated GLP-1 concentrations in response 
to an oral glucose tolerance test (OGTT). Although BAs are 
mainly released in response to fat ingestion, an increase in 
several plasma conjugated BAs was found after an OGTT 
[15, 16]. Thus, BAs, as well as (indirectly) the gastroin-
testinal hormone cholecystokinin (CCK) which stimulates 
gall bladder contraction, might also play a role in glucose 
metabolism after consumption of a carbohydrate-rich meal.
We were, therefore, interested in studying both the 
postprandial glucose kinetics and the metabolic responses 
to bread with a high and a low glycemic response, using 
wheat particle size as a variable factor. Postprandial glu-
cose responses to wheat products prepared with different 
flour or grain particle size have been shown to decrease 
with increasing particle size [17], likely explained by 
decreasing the rate of amylolysis. Replacement of finely 
ground wheat flour by increasing the proportion of cracked 
wheat in bread (to 50 and 75 %) also resulted in a reduction 
in GI [18].
In this crossover study, we investigated the metabolic 
effects of consumption of two 13C-labeled wheat breads, 
with the same overall composition, only varying in struc-
ture; a bread prepared with flour and 85 % broken wheat 
kernels and a control bread made from wheat flour com-
bined with wheat bran, to obtain a similar dietary fiber 
content in both breads. We hypothesized that, due to the 
variation in particle size, the glycemic response, the under-
lying glucose kinetics, and possibly other factors involved 
in glucose metabolism would be different between both 
breads.
Subjects and methods
Subjects
Ten healthy men [age 24 ± 0.6 years, BMI 22 ± 0.2 kg/
m2 (mean ± SEM)] were recruited. The main criteria for 
exclusion were use of medication, blood donation, or use of 
antibiotics in the past three months, gastrointestinal surgery 
or dysfunction, inflammatory diseases, and diabetes melli-
tus. Approval was obtained from the Medical Ethics Com-
mittee of the ‘Beoordeling Ethiek Biomedisch Onderzoek’ 
foundation, Assen, The Netherlands. Each subject gave 
written informed consent for the study. This trial was regis-
tered at trialregister.nl as NTR3020.
Experimental design
In the overall study design, addressing two different 
research questions, four different wheat-based products 
were tested. To increase clarity and be able to focus on 
the results of one of these questions, only two meals are 
described in this paper. A description of the other products 
and the results can be found elsewhere [19]. The study was 
performed in a randomized, crossover manner, with at least 
1 week between each study day. The subjects were asked 
to refrain from consuming foods naturally high in 13C, like 
cane sugar, corn products, and pineapple, for 3 days pre-
ceding the experiments and from alcohol consumption and 
strenuous exercise for 24 h before each study day. Food 
intake on the day before each study day was individually 
standardized. To minimize variation, a standard evening 
meal was provided at the commercial research facility (QPS 
Netherlands B.V.), where the participants stayed overnight. 
In the evening, a venous catheter was inserted in each 
forearm for blood collection and for infusion of the tracer 
D-[6,6-2H2]glucose (98 % 
2H atom percent excess, Iso-
tec) [20, 21]. Subjects fasted overnight, but were allowed 
to drink water. In the morning (t = −122 min), a bolus of 
26.7 mL D-[6,6-2H2]glucose solution (80 × 0.07 mg/kg 
body weight) was injected within 2 min, and a continu-
ous infusion of 0.07 mg/kg body weight D-[6,6-2H2]glu-
cose per min was started (t = −120 min) and maintained 
for 8 h (until t = 360 min). The bolus amount was 80× 
the infusion rate over 1 min, according to the paper of Tis-
sot et al [20]. The infusion rate over 1 min was 0.07 mg/kg 
BW [21], to reach a good steady state. So the continuous 
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infusion contained 4.2 mg/kg BW per 60 min, administered 
at a desired infusion rate of 20 mL/h, resulting in the con-
centration of 0.21 mg/mL/kg BW. The bolus had the same 
concentration, and therefore, to administer 80 × 0.07 mg/
kg BW an amount of 26.7 mL was administered.
Two hours after the start of the infusion the test meal 
was ingested (t = 0 min). Figure 1 shows a simplified 
time line of each study day. Water (150 mL) was provided 
hourly, starting at t = 120 min. During the study period 
physical activity was limited.
Test meals
Two types of wheat bread were prepared (TNO, Zeist, The 
Netherlands), with the same composition, but a different 
structure, due to different milling and bread making pro-
cesses; a kernel bread (KB) prepared with flour and 85 % 
broken wheat kernels, and a control bread (CB) made from 
wheat flour, combined with wheat bran, to obtain the same 
dietary fiber content as in the KB.
To provide the necessary ingredients, unlabeled 
(1.085 at.% 13C) wheat grains [T. aestivum var Capo, 
grown in Austria] were milled in different ways; by conven-
tional roller-milling the wheat kernels were milled to obtain 
refined white flour and wheat bran, and broken wheat ker-
nels were obtained using a breaker mill. For 13C-enrich-
ment of the products, 13C-labeled wheat [T. aestivum var 
Paragon (1.359 at.% 13C)], cultured in a 13CO2 enriched 
atmosphere, was used. A small part of the 13C-labeled 
wheat kernels was milled to obtain a fine wholemeal wheat 
flour, and the other part was broken to obtain broken ker-
nels that were similar to the unlabeled broken kernels.
CB was prepared with 1446 g unlabeled white wheat 
flour, 240 g 13C-labeled wholemeal wheat flour, 314 g 
wheat bran, 1300 g water, 33.4 g yeast, 36 g salt, 3 g malt, 
and 70 ppm ascorbic acid. After kneading, the dough was 
left to rise for 30 min, molded, and left to rise for 60 min. 
KB was prepared with 264 g unlabeled white wheat flour, 
36 g 13C-labeled wholemeal wheat flour, 1496 g unlabeled 
broken wheat kernels, and 204 g 13C-labeled broken wheat 
kernels. All broken kernels were soaked in 1000 g water 
overnight at 10 °C. The following day, the soaked kernels 
were mixed with the flour, 230 g water, 33.4 g yeast, 36 g 
salt, 3 g malt, and 70 ppm ascorbic acid. The resulting 
dough was left to rise for 30 min, molded, and left to rise 
for 50 min. Subsequently, the breads were baked for 30 min 
at 240 °C. Bread slices were stored at −20 °C until use.
All test meals provided 50 g available carbohydrates; for 
the CB, the portion size was 138 g and for the KB 137 g. 
The breads were consumed together with 10 g light mar-
garine (4 g fat), 2 slices lean ham (5 g fat, 6 g protein), 
and 250 mL tap water within 20 min. We assume that the 
digestibility of starch from both test products is similarly 
affected by this addition.
Bread characterization
Starch, dietary fiber, and moisture content were determined 
at Eurofins Analytico Food, The Netherlands. To quantify 
starch fractions (GT, GRA, GSA, GTA, and RS) of the test 
meals in vitro, an adapted version of the Englyst method 
[22] was used [23].
Particle size distribution of the broken kernels was deter-
mined by sieve analysis in duplicate.
Bread products volume (mL) was determined in tripli-
cate by rapeseed displacement (AACCI Method 10-05.01 
[24]) and, together with the bread weight (g), the product 
overall specific volume (mL/g) and density (g/mL) were 
obtained.
Breads were further characterized using microscopy 
and X-ray microtomography (XRT, porosity). A detailed 
description of both techniques can be found in Online 
Resource 1.
Sample collection
Blood was collected into several blood collection tubes 
(BD Diagnostics): 2 mL fluoride tubes (NaF) for glucose 
and bile acid measurements, 3 mL EDTA tubes [+30 µL 
DPP-4 inhibitor (Millipore)] for GIP, GLP-1, glucagon, 
Fig. 1  Simplified schematic 
time line of each study day. 
Blood was collected at 18 time 
points, indicated by inverted tri-
angle. Also, several breath and 
urine samples were collected 
during each study day
Connuous D-[6,6-2H2]glucose (0.07 mg/min/kg BW) (t = -120 unl t = 360 min) 
 -120  -60 0    60 120 180 240 300  360  min
Priming D-[6,6-2H2]glucose bolus infusion (t = -122 min) 
Ingeson 13C-enriched test meal (t = 0 min) 
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and insulin determination, and 3 mL lithium/heparin 
tubes (CCK). Three basal blood samples were collected 
(t = −60, −30, −15 min), and postprandial samples were 
drawn every 15 min for 2 h, every 30 min for an additional 
3 h, and once after 6 h. To obtain heparin plasma, blood 
was collected at t = −60, t = −15 min and then every 
30 min for the first 3 h, and hourly for the last 3 h. After 
centrifugation (1300×g for 10 min at 4 °C), plasma ali-
quots were stored at −20 °C (NaF and EDTA plasma) or 
−80 °C (heparin plasma) until analysis.
Breath samples were collected by breathing through a 
straw into 10 mL Exetainer® vials (Labco Limited). Two 
basal breath samples were collected (t = −30, t = −5 min), 
and after the test meal, a sample was taken every 30 min 
until t = 360 min.
To get an impression about the impact of the breads on 
appetite, subjects were asked to rate their feeling of appe-
tite (hunger) using a visual analog scale (VAS) at 15 min 
before and hourly after the test meal, although the number 
of subjects (n = 10) is insufficient to detect differences in 
these subjective measures [25]. At the same time points, 
their feeling and extent of discomfort (abdominal pain, 
flatulence, other complaints) was recorded (0 = no com-
plaints, 3 = severe complaints). Shortly after consumption 
of the meal, the subjects scored (VAS) how tasty the meal 
was.
Measurement of plasma concentrations
Plasma glucose concentrations were measured on a 
Roche/Hitachi Modular automatic analyzer (Roche Diag-
nostics, Hitachi) using a glucose hexokinase method. The 
within- and between-run CV were ≤2 %. The ARCHI-
TECT® insulin assay (Abbott Laboratories) was used to 
determine insulin concentrations in plasma. The total CV 
of this chemiluminescent microparticle immunoassay was 
≤7 %. The glucagon assay was directed against the C-ter-
minal of the glucagon molecule (antibody code no. 4305) 
and therefore measures glucagon of mainly pancreatic ori-
gin [26]. Total GIP was measured using the C-terminally 
directed antiserum (no. 80867) [27], which reacts fully 
with intact GIP (1-42) and the N-terminally truncated 
metabolite GIP (3-42). Total GLP-1 concentrations were 
determined as previously described [28], using a radioim-
munoassay (antiserum no. 89390) specific for the C-ter-
minal of the GLP-1 molecule and reacting equally with 
intact GLP-1 and the primary (N-terminally truncated) 
metabolite. The glucagon and incretin assays have detec-
tion limits of <2 pmol/L, and an intra-assay coefficient of 
variation of approximately 6 %. CCK was measured using 
antiserum no. 92128, which binds the bioactive forms of 
CCK with equal potency without cross-reactivity with 
any gastrin [29]. The detection limit of the CCK assay is 
0.1 pmol/L, and the intra-assay coefficient of variation 
approximately 5 %.
Measurement of plasma bile acids
Fasting and postprandial concentrations of 15 individual 
BAs were determined using LC/MS: the primary BAs 
[cholic acid (CA) and chenodeoxycholic acid (CDCA)], the 
secondary BAs [deoxycholic acid (DCA), ursodeoxycholic 
acid (UDCA), and lithocholic acid (LCA)], as well as their 
glycine (G, glyco-) and taurine (T, tauro-) conjugates. The 
lower limit of quantitation (LOQ) was 0.05 µM. Concen-
trations of TCA, LCA, GLCA, TLCA, TDCA, UDCA, and 
TUDCA were below the LOQ. The intra- and inter-assay 
CV ranged from 1.6 to 11.3 and 4.4 to 13.3 %, respectively. 
For sample preparation, 250 µl of internal standard solution 
was mixed with 25 µl plasma and centrifuged at 15.900×g 
for 10 min. The supernatant was transferred into a new vial, 
evaporated under nitrogen at 40 °C, and reconstituted in 
100 µl of 50 % methanol. The solution was filtered with a 
0.2-µm centrifugal filter at 2000×g for 10 min. After this 
step, the samples (injection volume 10 µl) were ready for 
analysis, using two different LC/MS systems. A detailed 
description of the systems and settings can be found in 
Online Resource 2.
Analysis of isotopic enrichment (breath and plasma) 
and calculations
Analysis of 13C abundance in breath CO2 was performed 
using GC/IRMS (Delta Plus XL; Thermo Fisher Scientific) 
measuring the 13C/12C ratio versus the international stand-
ard Pee Dee Belemnite (δ13CPDB, in ‰).
Plasma sample preparation required for analysis of iso-
topic enrichment by GC (derivatization) is described in 
detail elsewhere [30, 31]. 2H enrichment was measured 
by GC/MS as previously described [30], and 13C/12C iso-
tope ratio was measured using GC/C/IRMS as previously 
described [32], both with some modifications [33].
Calculation of glucose kinetics was performed as previ-
ously reported [34].
Incremental areas under the curve (iAUC)
To determine differences in glucose kinetics and plasma 
glucose, insulin, glucagon, incretin, CCK, and bile acid 
concentrations, the 0–2 and 0–6 h iAUCs were calculated 
as previously described [34].
Statistics
Human data are presented as mean ± SEM, n = 10. Base-
line-subtracted values are shown in the figures and were 
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used in the analyses as well, for clarity, consistency, and 
comparison of variables. The overall study involved testing 
of four test meals. From the statistical analysis of the full 
experiment, we highlight only the comparisons involving 
the products of current interest. For parameters that result 
in individual points of a time curve, we fitted a model that 
accounts for the differences between the 10 subjects and 
the four occasions, the main effects of treatment and time, 
respectively, and the time × treatment interaction. Residual 
plots based on such a model were used to assess approxi-
mate normality and homogeneity of variances. Parameters 
that were not compatible with these assumptions were 
transformed before definitive analysis. Most variables were 
log-transformed, except for glucose (reciprocal values), 
VAS scores (angular transformation), RaE, and 13CO2 val-
ues (Poisson regression model on log scale).
We performed F tests on time × treatment interaction 
effects to assess whether the four test meals gave rise to 
curves of a different shape. If the test resulted in a P value 
<0.05, we tested differences between the meals for each 
time point. If there were no statistically significant differ-
ences in shapes, we tested overall differences between the 
meals based on the above model without the time × treat-
ment interaction.
To assess summary measures such as iAUC, we fitted a 
model accounting for the differences in the means of the 
10 subjects and the four occasions, and the main effects of 
treatment. Transformed data were used whenever residual 
plots showed incompatibility with normality and homoge-
neity assumptions. We performed an F test to see whether 
there were differences between the meals. If this test 
resulted in a P value <0.05, pairwise comparisons among 
the meals were conducted.
A Benjamini–Hochberg correction was applied on P val-
ues from all partial tests to correct for multiple compari-
sons, resulting in a set of differences in which at most 5 % 
were falsely selected (P < 0.0052 for partial tests was con-
sidered significant). The analyses were performed with the 
software package GenStat, release 13. The within-subject 
relationship (correlation) between variables was tested by 
regression analysis according to the method of Bland and 
Altman [35]. Test meal differences (e.g., density, poros-
ity) were assessed using a Student’s t test; a P value <0.05 
was considered significant. These analyses were performed 
using SPSS 20.0 for Windows (SPSS Inc., Chicago).
Results
Characterization of test meals
The breads (CB and KB, respectively) were comparable in 
amount of starch (36.2 and 36.4 %), dietary fiber (7.6 and 
8.3 %), and moisture content (38.6 and 37.8 %). In vitro 
quantification of starch fractions showed similar digestive 
characteristics for CB and KB when a sample from the 
total bread was analyzed (Table 1).
A main difference between the two breads (Fig. 2a) 
was their density; CB had a density of 0.29 ± 0.007 g/
mL compared to 0.41 ± 0.003 g/mL for KB (P < 0.05). 
The difference in density was clearly visible in the prod-
uct structure (Fig. 2b). In the case of KB, 85 % of the 
wheat material consisted of broken kernels. The major-
ity (72.6 %) of the broken kernels had a particle size 
between 1680 and 2800 µm as measured by pan siev-
ing. Both visual evaluation and microscopy confirmed 
that the KB structure consisted of broken wheat kernels 
with a particle size of 1 to several mm (Fig. 2b). Light 
microscopy with starch (lugol; blue) and protein stain-
ing (Ponceau 2R; red) (Fig. 2c) showed that CB had a 
porous structure and the thin cell walls were dominated 
by a continuous phase of starch granules in blue. In this 
matrix bran particles were clearly visible as clusters 
of red aleurone cells aligned on the outer side by peri-
carp layers. An apparent difference was the presence 
of broken wheat kernels in which no starch granules 
(blue) were observed (Fig. 2c). Apparently, the matrix 
was governed by proteins (in red) embedding the starch 
granules.
A description of the porosity measurements of both 
breads using XRT can be found in Online Resource 1.
Postprandial glucose and insulin response
Postprandial glucose concentrations were similar after the 
consumption of CB and KB (Fig. 3a; Table 2). The insulin 
response was lower after KB consumption compared to CB 
at t = 60 min (P = 0.002) (Fig. 3b), which resulted in a 
31 % smaller iAUC (0–2 h) compared with CB intake (NS, 
P = 0.011).
Table 1  In vitro quantification of starch fractions in the test meals
CB control bread, GRA rapidly available glucose (20 min), GSA slowly 
available glucose (20–120 min), GT total glucose (indicated as 
100 %), GTA total available glucose (120 min), KB kernel bread, RS 
resistant starch
Starch fraction Test meal/portion
CB total KB total KB kernel KB crumb
%
GT 100 100 100 100
GRA 78.8 76.4 65.5 67.8
GSA 11.8 13.6 15.9 16.3
GTA 90.6 90.0 81.4 84.1
RS 8.4 9.0 16.7 14.3
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Glucose kinetics
The RaE was similar after CB and KB consumption 
(Fig. 4a), except for t = 120 min, where RaE was higher 
after CB intake (P = 0.005). EGP was not significantly dif-
ferent after consumption of CB and KB. The rate at which 
glucose was cleared from the circulation (GCR) was also 
similar (Fig. 4b; Table 2).
Postprandial incretin, glucagon, and CCK response
The average postprandial GIP response was somewhat 
higher after CB compared with KB intake (Fig. 5a; 
Table 2), but a significant difference was only found at 
t = 120 min (P < 0.005). The average GLP-1 response 
was higher after CB compared to KB consumption at 
each time point (Fig. 5b), resulting in a difference in the 
0–2 and 0–6 h iAUC (Table 2, P < 0.005). Differences 
between time points could, however, not be determined, 
as time × treatment interaction failed to reach significance 
(P = 0.073).
The postprandial glucagon response appeared higher 
after CB consumption, but no partial test (CB–KB) could 
be performed for iAUC. Also, differences between meals at 
individual time points could not be tested, as there was no 
time×treatment interaction (P = 0.9991).
Fig. 2  Pictures of 13C-enriched 
control and kernel bread: a 
overview; b stereo microscopy; 
c light microscopy with starch 
(lugol; blue) and protein (Pon-
ceau 2R; red) staining
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There was a slight increase in CCK concentrations in 
response to the test meals, which seemed somewhat lower 
after the KB from 90 min postprandial (Fig. 6a; Table 2), 
although differences were not significant (iAUC 0–6 h, 
P = 0.03).
Postprandial bile acid response
The postprandial pattern of glycine and taurine conjugated 
BAs in plasma was intra-individually identical, with the 
highest concentrations for GCDCA, followed by either 
GDCA or GCA. The unconjugated BAs (primary and sec-
ondary) also responded in the same way within each per-
son per test period. Therefore, by summing up concentra-
tions, individual BAs were grouped as conjugated and 
unconjugated BAs, and together they formed the total BA 
response (Fig. 6b). Unconjugated BAs in plasma showed a 
decrease after test meal consumption (Fig. 6c), whereas the 
conjugated BAs increased postprandial and peaked around 
t = 30 min (Fig. 6d). After CB consumption, conjugated 
BAs showed a second peak around t = 120 min. Due to the 
great inter-individual variation in postprandial responses, 
F tests did not result in significant P values, so differences 
between CB and KB could not be tested.
13CO2 excretion in breath
13CO2 excretion in breath, reflecting the rate of oxidation of 
the 13C-labeled substrate, was higher after CB consumption 
at t = 210 min (P = 0.0014). The time to peak was not dif-
ferent after the meals, but the peak value was significantly 
higher after CB consumption (P = 0.005) (Table 2).
Correlations
Correlations between several variables (all time points, 
0–6 h; P < 0.05) were determined (Table 3). RaE and 
GIP were very well correlated, especially for CB (CB, 
r = 0.84; KB, r = 0.71). RaE and GLP-1 showed a mod-
erate correlation (CB, r = 0.70; KB, r = 0.58). The cor-
relation between GLP-1 and conjugated BAs was moderate 
for CB (r = 0.60) and lower for KB (r = 0.39). Total BAs 
with GLP-1 showed similar correlation coefficients (CB, 
r = 0.53; KB, r = 0.43).
Rated appetite, discomfort, and liking of test meal
The subjective sensation of appetite (hunger), as deter-
mined hourly using a VAS, was similar after consumption 
of CB and KB (data not shown). Occasional mild com-
plaints about flatulence were not meal type related. The 
liking of the test meal was rated by using a VAS (0 = not 
tasty, 100 = very tasty). The resulting scores (CB = 57, 
KB = 33) indicate that the KB was not well appreciated by 
the subjects.
Discussion
This paper describes the glucose kinetics and metabolic 
effects in healthy men after consumption of control bread 
(CB) and 85 % broken kernel bread (KB). We expected 
that consumption of KB would result in a low glycemic 
response due to slower digestion of starch in the larger 
wheat kernel particles [17, 18]. However, the postprandial 
glycemic response did not differ after consumption of our 
breads. Although a similar glycemic response does not 
exclude a difference in  in vivo starch digestibility due to 
possible differences in GCR [33, 34] or EGP, the present 
study found no pronounced differences in glucose kinet-
ics. The RaE, reflecting intestinal glucose uptake, as well 
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Fig. 3  Mean (±SEM) changes from baseline in a plasma glucose 
concentrations and b plasma insulin concentrations, after inges-
tion of 138 g 13C-enriched control bread (filled circle) and 137 g 
13C-enriched kernel bread (open diamond) in healthy men (n = 10). 
There was no significant time × treatment interaction for glucose 
(P = 0.1773), but there was for insulin (P < 0.0001). Asterisk signifi-
cantly different between treatments per time point (after Benjamini–
Hochberg correction)
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Table 2  Indices reflecting 
the metabolic response after 
ingestion of 138 g 13C-enriched 
control bread and 137 g 
13C-enriched kernel bread in 
healthy men
Values are mean ± SEM, n = 10
BA bile acid, CB control bread, CCK cholecystokinin, EGP endogenous glucose production, GCR glucose 
clearance rate, GIP glucose-dependent insulinotropic polypeptide, GLP-1 glucagon-like peptide-1, iAUC 
incremental area under the curve, KB kernel bread, RaE rate of appearance of exogenous glucose, RaT rate 
of appearance of total glucose
a Significantly different from control bread
b Because EGP and unconjugated BAs were suppressed after the test meals, the nadir values and time to 
nadir are presented. Also, the area beneath baseline (dAUC) was calculated using mirrored data
Fasting values Peak values Time to peak (min) iAUC (0–2 h) iAUC (0–6 h)
Glucose (mmol/L)
 CB 5.1 ± 0.1 8.3 ± 0.3 40.5 ± 3.2 163.2 ± 20.5 197.0 ± 23.4
 KB 5.0 ± 0.1 8.2 ± 0.3 34.5 ± 2.3 159.4 ± 30.1 195.4 ± 35.4
Insulin (µU/mL)
 CB 4.9 ± 0.5 69.9 ± 10.5 43.5 ± 3.5 3290.9 ± 528.8 4193.0 ± 936.6
 KB 5.0 ± 0.5 48.7 ± 4.5 36.0 ± 2.4 2262.1 ± 205.4 2707.6 ± 292.9
Glucagon (pmol/L)
 CB 8.3 ± 1.0 15.8 ± 1.7 175.5 ± 33.4 272.9 ± 84.6 980.5 ± 163.4
 KB 10.4 ± 1.2 16.8 ± 2.3 136.5 ± 38.2 207.1 ± 89.4 706.8 ± 199.9
GIP (pmol/L)
 CB 9.2 ± 1.8 84.9 ± 10.5 93.0 ± 13.6 4904.6 ± 426.7 9089.2 ± 1137.8
 KB 12.4 ± 1.6 74.5 ± 11.0 84.0 ± 13.5 4494.8 ± 743.1 7169.4 ± 989.0
GLP-1 (pmol/L)
 CB 15.5 ± 1.4 30.9 ± 2.1 86.3 ± 15.7 949.9 ± 95.0 2019.9 ± 183.0
 KB 18.3 ± 1.6 30.2 ± 1.8 76.5 ± 16.9 594.7 ± 102.4a 1167.0 ± 295.3a
RaT (mg/kg min)
 CB 2.0 ± 0.1 6.5 ± 0.3 57.0 ± 14.5 39.1 ± 1.4 88.1 ± 1.6
 KB 2.0 ± 0.0 6.8 ± 0.3 36.0 ± 6.0 38.2 ± 1.1 85.1 ± 1.4
RaE (mg/kg min)
 CB 0 ± 0 4.9 ± 0.2 66.0 ± 14.9 49.7 ± 1.6 95.9 ± 4.7
 KB 0 ± 0 4.9 ± 0.2 42.0 ± 12.0 46.9 ± 1.7 89.1 ± 1.8
EGP (mg/kg min)b
 CB 2.0 ± 0.1 0.9 ± 0.2 111.0 ± 12.1 43.4 ± 9.3 157.8 ± 26.7
 KB 2.0 ± 0.0 0.9 ± 0.2 117.0 ± 23.7 40.8 ± 8.8 151.4 ± 24.3
GCR (mL/kg min)
 CB 2.5 ± 0.1 6.4 ± 0.2 100.5 ± 12.5 15.6 ± 1.5 32.7 ± 1.7
 KB 2.5 ± 0.1 6.1 ± 0.3 85.5 ± 12.3 15.5 ± 1.9 30.9 ± 2.9
13CO2 (% dose/h)
 CB 0 ± 0 7.7 ± 0.2 228.0 ± 9.2 4.3 ± 0.3 31.7 ± 0.7
 KB 0 ± 0 7.2 ± 0.2a 237.0 ± 7.0 4.2 ± 0.2 30.0 ± 0.8
CCK (pmol/L)
 CB 0.5 ± 0.1 2.6 ± 0.3 115.5 ± 10.5 142.4 ± 5.7 295.0 ± 26.4
 KB 0.6 ± 0.1 2.2 ± 0.1 126.0 ± 14.0 132.0 ± 13.6 243.0 ± 26.2
Total BA (µmol/L)
 CB 2.1 ± 0.4 4.3 ± 0.7 61.5 ± 19.7 93.0 ± 23.3 171.2 ± 40.9
 KB 2.1 ± 0.6 4.2 ± 0.7 63.0 ± 21.1 80.3 ± 18.1 139.8 ± 42.8
Conjugated BA (µmol/L)
 CB 1.2 ± 0.3 3.6 ± 0.6 63.0 ± 19.3 110.8 ± 21.3 216.2 ± 43.4
 KB 1.0 ± 0.3 3.3 ± 0.4 64.5 ± 20.7 108.7 ± 24.9 204.5 ± 43.8
Unconjugated BA (µmol/L)b
 CB 0.9 ± 0.3 0.2 ± 0.1 211.5 ± 38.0 47.7 ± 26.9 185.2 ± 96.9
 KB 1.1 ± 0.5 0.2 ± 0.0 257.3 ± 41.3 60.2 ± 40.5 260.2 ± 160.9
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as the GCR and EGP, was similar after KB compared to 
CB. However, a clear difference in GLP-1 responses was 
observed after consumption of the test meals.
The use of intact grain kernels in bread formulations 
has been reported to reduce the glucose response by lim-
iting starch gelatinization and forming a physical barrier 
for α-amylase, reducing amylolysis [36]. For instance, 
the incorporation of 80 % preboiled whole wheat kernels 
[37, 38] showed the expected lowering effect of incorpo-
rated kernels on the glycemic response. However, the use 
of intact kernels per se does not necessarily induce a low 
GI, as incorporation of oat kernels showed less effect on 
glycemia [38]. Considering the palatability of the breads, 
we chose to incorporate broken wheat kernels and not 
intact kernels in KB, because the replacement of flour 
(50 and 75 % [18]) with cracked wheat was also previ-
ously reported to result in a reduction in GI. The broken 
kernels were soaked overnight to prevent difficulties in 
chewing. Even though the broken kernels in KB were still 
clearly visible, during preparation of the dough the soaked 
kernels were thoroughly kneaded together with other ingre-
dients, which might have further destructured the kernels, 
thus increasing starch accessibility to amylolysis. Breads 
were extensively characterized to document the impact of 
addition of broken kernels. The porosity, the average size 
of air cell diameter, and air cell distribution were not sig-
nificantly different between both breads. However, KB did 
have a higher density, which in itself is a characteristic that 
could give rise to a lower glycemic response [39]. Moreo-
ver, the average air cell wall thickness of KB was signifi-
cantly increased compared to CB, but these differences 
were apparently not large enough to evoke a difference in 
glucose response or kinetics.
Despite the similarities in the glycemic response, the 
GLP-1 response was much lower after KB consumption 
compared to CB (iAUC, P < 0.005). Nutrient ingestion 
is the main stimulus to L cells, which are described as an 
open type cell, enabling direct stimulation and release of 
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1072 Eur J Nutr (2017) 56:1063–1076
1 3
GLP-1 by luminal contact [40]. Although several mecha-
nisms have been proposed with respect to glucose sensing, 
in the early postprandial phase GLP-1 secretion seems to 
mainly involve the SGLT-1 glucose transporter in L cells, 
similar to GIP secretion from K cells [41, 42]. In the pre-
sent study, glucose transport across the intestinal mem-
brane is reflected by the RaE, which correlated well with 
GLP-1 concentrations after the CB (r = 0.70, P < 0.01), 
but more moderately after the KB (r = 0.58, P < 0.01). 
However, the correlations of RaE with GIP (CB: r = 0.84 
and KB: r = 0.71, P < 0.01), which are in accordance with 
our previous studies [31, 34], were stronger. The involve-
ment of additional factors in stimulating GLP-1 release in 
the present study is thus likely.
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Table 3  Correlation 
coefficients relating the glucose, 
insulin, GIP, GLP-1, conjugated 
and total BA concentrations, 
and RaE after ingestion of 138 g 
13C-enriched CB and 137 g 
13C-enriched KB
The within-subject relationship (correlation) between variables was tested by regression analysis according 
to the method of Bland and Altman [35], P < 0.05
BA con conjugated bile acids, BA tot total bile acids, CB control bread, GIP glucose-dependent insulino-
tropic polypeptide, GLP-1 glucagon-like peptide-1, KB kernel bread, RaE rate of appearance of exogenous 
glucose
Glucose Insulin GIP GLP-1 RaE BA con BA tot
CB KB CB KB CB KB CB KB CB KB CB KB CB KB
Glucose
Insulin 0.86 0.83
GIP 0.57 0.56 0.55 0.63
GLP-1 0.41 0.43 0.41 0.46 0.59 0.69
RaE 0.73 0.71 0.66 0.76 0.84 0.71 0.70 0.58
BA con 0.21 0.24 0.18 0.41 0.34 0.27 0.60 0.39 0.41 0.38
BA tot 0.23 0.25 0.19 0.39 0.26 0.25 0.53 0.43 0.35 0.27 0.94 0.89
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We expected that due to the larger particle size in KB, 
more starch would reach the more abundant distal L cells, 
resulting in an increased late postprandial GLP-1 response. 
This was, for instance, seen in a study with slowly digesti-
ble starch, together with a prolonged influx of glucose [31]. 
However, the GLP-1 response was prolonged after CB, but 
not after KB consumption, even though intestinal glucose 
uptake did not differ between our breads.
Moreover, with inhibition of SGLT-1 and in SGLT-1-/-
mice, a late prolonged increase in GLP-1 after a glucose load 
was observed [43], besides the decreased GIP and GLP-1 
responses in the early postprandial phase [41, 42]. This indi-
cates that the late postprandial GLP-1 response might not 
require glucose absorption via SGLT-1 [43]. Because L cells 
are densely distributed in the distal small intestine and colon, 
it might be that only the presence of still unabsorbed carbohy-
drates is important in stimulating GLP-1 in the late postpran-
dial phase, for instance via other glucose-sensing mechanisms.
A prolonged postprandial GLP-1 response was also 
observed when sucrose digestion was delayed by acarbose 
[44, 45], which was linked to a simultaneous increase in 
breath hydrogen after 60–120 min, related to fermentation 
of sucrose. Another explanation for GLP-1 secretion in the 
late postprandial phase is therefore the involvement of short 
chain fatty acids (SCFAs), produced during fermentation of 
unabsorbed carbohydrates or fiber by the intestinal micro-
biota, and known to stimulate GLP-1 secretion as well [46]. 
Although fermentation of solid food may be expected in a 
later phase, in a previous study using 13C-labeled barley, 
13C-labeled SCFAs in plasma were detected within 3 h after 
ingestion [23]. Increased SCFA formation after CB may be 
expected due to the presence of finer wheat bran [47].
In addition to nutrients and SCFAs, BAs are also able 
to potentiate GLP-1 release via activation of the BA recep-
tor TGR5 [13, 14, 48]. Besides in vitro and animal data, 
in healthy humans, jejunal infusion with TCA and glucose 
increased GLP-1 concentrations [49]. In our study, conju-
gated bile acids in plasma increased, whereas the unconju-
gated BAs decreased after bread consumption. These obser-
vations are in agreement with those of others made after an 
OGTT [50, 51]. However, to the best of our knowledge, so 
far the differences in BA responses after various starchy food 
products have not yet been investigated. After KB consump-
tion, the total BA response tended to be lower compared to 
CB (from t = 90 min), but differences were not significant 
and large inter-individual variations were observed. CCK, 
involved in regulating gall bladder contraction and thus BA 
release, showed only a slight increase in response to the 
test meals, which also tended to be somewhat lower for KB 
between 90 and 180 min postprandial. However, an apparent 
difference between CCK and BA response patterns was the 
peak in BA concentration during the first 60 min, which was 
not detected in the CCK response in the present study.
We found a moderate correlation between GLP-1 and 
total BAs (CB r = 0.53, KB r = 0.43) and GLP-1 and con-
jugated BAs (CB r = 0.60, KB r = 0.39), indicating that 
there may be a relationship between the BA and GLP-1 
response. In agreement, another study found a correlation 
of GLP-1 with mainly glycine-conjugated BAs and total 
BAs after ingestion of a mixed meal [52]. The correla-
tion coefficients for KB were clearly lower compared to 
CB, and as mentioned earlier, lower values for KB were 
also observed when correlating RaE with GIP and GLP-1. 
Because the interactions are likely to happen in the intes-
tine, it might be that the more preserved kernel structure in 
KB resulted in less accurate glucose-sensing or interfered 
in BA binding by the K and/or L cells.
It should also be kept in mind that the BAs measured in 
the systemic circulation do not necessarily directly reflect 
what happens in the intestine as, for instance, reabsorption 
of BAs might be influenced by food components. Fiber was 
found to bind BAs to a certain extent [53], and with respect 
to bran, especially more finely milled wheat bran was sug-
gested to have higher BA binding capacity [54]. Thus, the 
finer wheat bran fiber in CB could have bound more BAs, 
preventing reabsorption and resulting in higher exposure of 
the L cells to BAs in the distal small intestine and colon, 
thereby contributing to the higher late GLP-1 response after 
CB. In support of this, it was shown in rodents that BA 
sequestrant administration could increase fecal BAs, stim-
ulate TGR5 on L cells located in the colon, and increase 
postprandial GLP-1 concentrations [55]. Moreover, rectal 
infusion of TCA in obese T2DM patients resulted in a pro-
nounced, dose-dependent GLP-1 response [56].
More research is necessary to understand the complex 
regulation of postprandial GLP-1 stimulation and the possi-
ble role of BAs. Therapies that increase BAs (or mimetics) 
in the distal bowel as a means of increasing endogenous 
GLP-1 concentrations have been suggested as novel treat-
ments of T2DM and obesity [56]. Several other approaches 
to increase GLP-1 action are being intensively studied for 
their potential therapeutic use. Furthermore, because of the 
beneficial effects in T2DM patients, treatment with GLP-1 
analogs was also proposed for people with prediabetes to 
prevent progression to T2DM [57, 58]. Pharmaceutical 
intervention might, however, have downsides, and increas-
ing endogenous GLP-1 concentrations by nutritional means 
would therefore be interesting.
Some potential limitations of this study should be con-
sidered. The breads were frozen after baking, to keep 
them fresh during the whole study period (4-week). Dif-
ferential effects on digestibility of starch in the control 
or kernel bread cannot be excluded. Furthermore, we did 
not measure the protein content of the products. Protein 
can affect the blood glucose response, by influencing the 
insulin response independent of carbohydrates. However, 
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we expected the protein content to be very similar, as both 
breads were made from the same wheat type and also had 
the same starch content.
To conclude, the substitution of 85 % wheat flour by 
broken kernels in bread did not result in any difference in 
glucose response and kinetics, but did elicit a pronounced 
difference in GLP-1 responses. Because of the complex 
regulation of GLP-1 release, several factors could simul-
taneously play a role after consumption of food products 
such as bread. Plasma bile acids showed a pronounced 
response after the breads, which might play a role in GLP-1 
stimulation.
Our findings show that the glycemic response is not 
the only parameter which can determine health effects of 
starchy foods. The GLP-1 response is apparently largely 
independent from glucose kinetics and might be influenced 
by other characteristics of starchy food products. There-
fore, our finding shows that bread processing technology 
can influence metabolic response beyond glycemia, which 
offers significant opportunities.
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